Latest KFF Health News Stories
World-Famous Wall Drug Isn’t Immune From Challenges Facing Rural Pharmacies
Even as part of a popular South Dakota tourist attraction, an independent pharmacy serving locals, remote ranchers, and sightseers struggles with staffing and insurer payments.
Louisiana Reclassifies Drugs Used in Abortions as Controlled Dangerous Substances
Louisiana lawmakers have added two drugs commonly used in pregnancy and reproductive health care to the state’s list of controlled dangerous substances, a move that has alarmed doctors in the state.
Qué son los medicamentos compuestos que millones de personas usan para bajar de peso
La FDA permite e incluso fomenta que las farmacias de compuestos produzcan y vendan copias cuando un medicamento está en escasez, como es el caso de las drogas para combatir el sobrepeso y la obesidad.
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
Harris, alguna vez la voz de Biden sobre el aborto, tendría un enfoque abierto en temas de salud
Mientras los demócratas reconstruyen su candidatura presidencial a pocos meses de las elecciones, se esperaría que, de ser la nueva nominada, Harris adoptase una postura agresiva en apoyo al acceso al aborto y en otros temas controversiales de salud.
Harris, Once Biden’s Voice on Abortion, Would Take an Outspoken Approach to Health
If she grabs the baton from President Joe Biden to become the new presumptive Democratic presidential nominee, Kamala Harris would widely be expected to take an aggressive stance in support of abortion access — hitting former President Donald Trump on an issue that could undermine his chances of victory.
The Supreme Court Just Limited Federal Power. Health Care Is Feeling the Shockwaves.
A Supreme Court ruling restricting federal power will likely have seismic ramifications for health policy. A flood of litigation — with plaintiffs like small businesses, drugmakers, and hospitals challenging regulations they say are too expensive or burdensome and not authorized by law — could leave the country with a patchwork of disparate health regulations.
KFF Health News' 'What the Health?': SCOTUS Rejects Abortion Pill Challenge — For Now
The Supreme Court has dismissed a challenge to the FDA’s approval of the abortion pill mifepristone, ruling unanimously that the anti-abortion doctor group that filed the suit lacked standing. But abortion opponents are expected to pursue other strategies to ban or restrict the medication. Meanwhile, the Biden administration moves to stop the inclusion of medical debt on individual credit reports, and former President Donald Trump tries to claim credit for $35 insulin. Anna Edney of Bloomberg News, Rachana Pradhan of KFF Health News, and Emmarie Huetteman of KFF Health News join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF president and CEO Drew Altman about KFF’s new “Health Policy 101” primer.
Biden Plan To Save Medicare Patients Money on Drugs Risks Empty Shelves, Pharmacists Say
President Joe Biden is campaigning for reelection on his efforts to cut costs for Medicare patients at the pharmacy counter. But independent pharmacists say one strategy makes it unaffordable for them to keep some brand-name medicines in stock.
Weight-Loss Drugs Are So Popular They’re Headed for Medicare Negotiations
The steep prices — and popularity — of Ozempic and similar weight-loss and diabetes drugs could soon make them a priority for Medicare drug price negotiations. List prices for a month’s supply of the drugs range from $936 to $1,349, according to the Peterson-KFF Health System Tracker. The Inflation Reduction Act President Biden signed in […]
Readers Issue Rx for Clogged ERs and Outrageous Out-of-Pocket Costs
KFF Health News gives readers a chance to comment on a recent batch of stories.
Journalists Talk Cost of Weight Loss Drugs and Lack of Obesity Doctors to Manage Their Use
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss topical stories. Here’s a collection of their appearances.
KFF Health News' 'What the Health?': Waiting for SCOTUS
June is when the Supreme Court typically issues rulings in the major cases it hears during that year’s term. This year, those interested in health policy are awaiting decisions in two abortion-related cases and one that could reshuffle the way health policies (and all other federal policies) are made. In this special episode, KFF’s Laurie Sobel, associate director for women’s health policy, joins Julie Rovner for a review of the cases and a preview of how the court might rule.
An Obscure Drug Discount Program Stifles Use of Federal Lifeline by Rural Hospitals
A disconnect between two federal programs meant to help keep hospitals afloat discourages struggling rural facilities from accepting the aid.
Journalists Zero In on Bird Flu and Weight Loss Drugs
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Treatment
The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
Personas de bajos ingresos no pueden recibir terapias efectivas contra la diabetes por el alto costo
La escasez de suministros y las barreras que ponen las aseguradoras para obtener esta poderosa clase de medicamentos, llamados agonistas de GLP-1, han dejado a muchas personas que viven con diabetes y obesidad sin los medicamentos que necesitan para mantenerse saludables.
Journalists Broach Topics From Treating Shooting Victims to Sunscreen Safety
KFF Health News and California Healthline staffers made the rounds on national and local media in the last couple of weeks to discuss topical stories. Here’s a collection of their appearances.
Clean Needles Save Lives. In Some States, They Might Not Be Legal.
As billions of dollars from settlements with opioid manufacturers and distributors go to state and local governments, efforts to reduce the epidemic’s harm can be hamstrung by drug paraphernalia laws. Health authorities say distributing clean syringes to users can save lives, but in states like Pennsylvania, it may be illegal.
Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge
The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose — which earns it an additional $180,000 a year per patient.
